Innovative Research Award
Jinshun Xu
Sichuan Cancer Hospital, China
Jinshun Xu is a Chinese physician-scientist and researcher at Sichuan Cancer Hospital whose work focuses on biomedical nanotechnology, ultrasound medicine, cancer imaging, and image-guided therapeutic interventions. His research has contributed to the development of microwave-responsive nanocarriers, ultrasound-mediated drug delivery systems, and immune-enhanced cancer therapies. These contributions reflect the type of interdisciplinary innovation and translational research recognized by the Innovative Research Award.[1]
Abstract
Jinshun Xu is a Chinese physician-scientist whose research focuses on the convergence of biomedical nanotechnology, ultrasound medicine, molecular imaging, and minimally invasive oncologic therapies. His investigations have emphasized microwave-responsive nanocarriers, ultrasound-mediated drug delivery systems, image-guided ablation strategies, and immune-enhancing therapeutic platforms. Through multidisciplinary collaborations, he has contributed to the development of advanced treatment approaches for hepatocellular carcinoma, breast cancer, prostate cancer, and other malignancies. His publication record, citation performance, and leadership of nationally and provincially funded research projects demonstrate substantial scientific productivity and translational relevance.[2]
Keywords
Biomedical Nanotechnology; Ultrasound Medicine; Cancer Imaging; Microwave Ablation; Nanocarriers; Immunotherapy; Molecular Imaging; Drug Delivery Systems; Oncology Research; Translational Medicine.
Introduction
Modern cancer research increasingly depends upon interdisciplinary approaches that integrate engineering, nanotechnology, imaging sciences, and clinical medicine. Researchers working at these interfaces play an important role in advancing precision medicine and minimally invasive therapeutic strategies. Jinshun Xu’s academic career reflects this multidisciplinary paradigm through contributions spanning ultrasound-guided interventions, microwave-responsive therapeutic systems, and nano-enabled cancer treatments.[3]
Research Profile
Jinshun Xu currently serves as Deputy Director of the Department of Ultrasound Medicine at Sichuan Cancer Hospital. His research program encompasses molecular imaging, nanomedicine, thermal ablation technologies, targeted drug delivery, ultrasound-responsive biomaterials, and cancer immunotherapy. He has led multiple competitive research projects funded by provincial foundations, university programs, and national scientific agencies, demonstrating sustained research leadership.[1]
Research Contributions
Jinshun Xu’s work involves the design of microwave-responsive nanoplatforms capable of enhancing local tumor ablation while simultaneously promoting immune activation. These systems have been investigated as strategies to improve treatment efficacy and address metastatic disease progression through combined thermal, dynamic, and immunotherapeutic mechanisms.[4]
Publications
- Microwave ablation of benign breast tumors: a prospective study with minimum 12 months follow-up (International Journal of Hyperthermia, 2018).
- Ultrasound-responsive nanocarriers for cancer therapy: Physiochemical features-directed design (Journal of Controlled Release, 2025).
- Review of clinical tumor ablation advance in Asia (International Journal of Hyperthermia, 2021).
- Phase-transitional Fe3O4/perfluorohexane microspheres for magnetic droplet vaporization (Theranostics, 2017).[5]
Research Impact
Jinshun Xu’s research is reflected in a Scopus profile reporting 57 indexed documents, more than 800 citations, and an h-index of 15. These indicators suggest consistent scholarly engagement and recognition within biomedical engineering, oncology, imaging science, and nanomedicine communities.[1]
Beyond publication metrics, his work has contributed to the advancement of translational technologies that bridge laboratory innovation and clinical implementation.[4]
Award Suitability
Jinshun Xu demonstrates characteristics commonly associated with candidates for the Innovative Research Award. These include interdisciplinary scientific contributions, leadership in externally funded research programs, development of emerging therapeutic technologies, and publication of influential work in high-impact journals. His investigations into microwave-responsive nanomedicine, ultrasound-guided interventions, and immune-enhanced cancer therapies align closely with contemporary priorities in translational biomedical research.[2][1]
Conclusion
Jinshun Xu has established a research career characterized by innovation in biomedical nanotechnology, ultrasound medicine, and image-guided cancer therapy. His contributions span fundamental nanomaterial development, translational therapeutic engineering, and clinical evaluation of advanced treatment approaches. Through a combination of scientific productivity, collaborative research leadership, and translational impact, he represents a strong candidate for recognition through the Innovative Research Award.
External Links
References
- Elsevier. (n.d.). Scopus author details: Jinshun Xu, Author ID 56666258500. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=56666258500
- Xu J., et al. (2026). Microwave-responsive nanocarrier-unlocked thermal-dynamic-immunotherapy: Rational physicochemical design-determined immunomodulation. Coordination Chemistry Reviews.
https://doi.org/10.1016/j.ccr.2026.218126
- Xu J., et al. (2026). Magnetic Hyperthermia Ablation of Tumors Using Injectable Fe3O4/Calcium Phosphate Cement. ACS applied materials & interfaces
https://pubs.acs.org/doi/abs/10.1021/acsami.5b02077
- Cheng X., Xu J., et al. (2024). A tumor-homing nanoframework for synergistic microwave tumor ablation and provoking strong anticancer immunity against metastasis. ACS Nano.
https://pubs.acs.org/doi/abs/10.1021/acsnano.4c10603
- Xu J., Cheng X., et al. (2019). Microwave responsive nanoplatform via p-selectin mediated drug delivery for treatment of hepatocellular carcinoma with distant metastasis. Nano Letters.
https://pubs.acs.org/doi/abs/10.1021/acs.nanolett.8b05202